Children with malignant tumors receiving immunnodepressivnuyu therapy, as well as blood, not bolevshie in the past, wind smallpox, after contact with it should be classified as at risk.
1. The use and dose. VZIG introduced intramuscularly. It contains 10 to 18% globulin and timerosal 1:10000 as preservatives, 1 vial (approximate volume of 1.25 ml) – This 125 ED, which is the minimum dose for every 10 kg. The maximum recommended dose – 625 ED (ie, 5 vials). VZIG the most effective if put in 48 hours, but no later than 96 hours after contact. The drug is not desirable to designate patients with haemorrhagic diathesis and should never be put intravenously. Following intramuscular injection, there is often a local discomfort.
2. Indications. The following persons should receive VZIG.
Children are at risk. It is necessary to introduce VZIG receptive to children under the age of 15 with immunodepressiey, which was long home contact or were in hospital wards for 4 or less beds, or playing in the same room at least one hour with the children, the sick wind smallpox in the contagious stage. Adolescents aged over 15 and adults with immune deficiency, probably immune, but if they are receptive, they should also introduce VZIG. Hospital patients desirable to write as possible within 10 days after contact. Otherwise they should be placed under strict isolation to 28-day post-exposure. Introduction VZIG may lengthen the duration of the incubation period.
Healthy adults. It is desirable to use VZIG healthy adults after close contact with VZV infection, especially if they are likely susceptibility. However, if possible, should conduct laboratory testing, as well as in adults with negative or uncertain history of wind ospe very likely existence of immunity.